Pages that link to "Q38448723"
Jump to navigation
Jump to search
The following pages link to The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model (Q38448723):
Displaying 50 items.
- RLIP76, a non-ABC transporter, and drug resistance in epilepsy (Q24533543) (← links)
- P-glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociception (Q24631289) (← links)
- Bypassing P-Glycoprotein Drug Efflux Mechanisms: Possible Applications in Pharmacoresistant Schizophrenia Therapy (Q26780502) (← links)
- Transporters at CNS barrier sites: obstacles or opportunities for drug delivery? (Q27690256) (← links)
- CYP2D6 polymorphisms and their influence on risperidone treatment (Q28079227) (← links)
- Enhanced brain disposition and effects of Δ9-tetrahydrocannabinol in P-glycoprotein and breast cancer resistance protein knockout mice (Q28482464) (← links)
- Treatment of autoimmune inflammation by a TLR7 ligand regulating the innate immune system (Q28484146) (← links)
- Antidepressants inhibit DNA methyltransferase 1 through reducing G9a levels (Q28564940) (← links)
- P-glycoprotein inhibition increases the brain distribution and antidepressant-like activity of escitalopram in rodents (Q30544869) (← links)
- Expression of HNF4alpha in the human and rat choroid plexus: implications for drug transport across the blood-cerebrospinal-fluid (CSF) barrier (Q33478002) (← links)
- Pharmacokinetic comparison to determine the mechanisms underlying the differential efficacies of cationic diamidines against first- and second-stage human African trypanosomiasis (Q33798222) (← links)
- Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery (Q33946973) (← links)
- Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy. (Q33992722) (← links)
- Emerging treatments in the management of schizophrenia - focus on sertindole (Q34129334) (← links)
- 5-HT4 receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment (Q34169814) (← links)
- Relationship between P-glycoprotein and second-generation antipsychotics. (Q34208133) (← links)
- Characterization of a novel brain barrier ex vivo insect-based P-glycoprotein screening model. (Q34292573) (← links)
- ABC multidrug transporters: structure, function and role in chemoresistance. (Q34586418) (← links)
- Sucralose, a synthetic organochlorine sweetener: overview of biological issues (Q34657381) (← links)
- A Multifaceted GABAA Receptor Modulator: Functional Properties and Mechanism of Action of the Sedative-Hypnotic and Recreational Drug Methaqualone (Quaalude) (Q34661183) (← links)
- Prediction of brain clozapine and norclozapine concentrations in humans from a scaled pharmacokinetic model for rat brain and plasma pharmacokinetics (Q34667775) (← links)
- Challenges for blood-brain barrier (BBB) screening (Q34707666) (← links)
- The antipsychotic potential of l-stepholidine--a naturally occurring dopamine receptor D1 agonist and D2 antagonist (Q34784192) (← links)
- ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors (Q35171274) (← links)
- Sertraline-induced potentiation of the CYP3A4-dependent neurotoxicity of carbamazepine: an in vitro study (Q35551134) (← links)
- Identification of trichlormethiazide as a Mdr1a/b gene expression enhancer via a dual secretion-based promoter assay. (Q35563239) (← links)
- Choroid plexus transport: gene deletion studies (Q35596169) (← links)
- Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings (Q35708089) (← links)
- Comparative Pharmacology of Risperidone and Paliperidone (Q35807345) (← links)
- Tertiary Amine Pyrazolones and Their Salts as Inhibitors of Mutant Superoxide Dismutase 1-Dependent Protein Aggregation for the Treatment of Amyotrophic Lateral Sclerosis. (Q35956262) (← links)
- Behavioral effects and central nervous system levels of the broadly available κ-agonist hallucinogen salvinorin A are affected by P-glycoprotein modulation in vivo (Q35996706) (← links)
- Use of biopartitioning micellar chromatography and RP-HPLC for the determination of blood-brain barrier penetration of α-adrenergic/imidazoline receptor ligands, and QSPR analysis (Q36319277) (← links)
- 1α,25-Dihydroxyvitamin D3-liganded vitamin D receptor increases expression and transport activity of P-glycoprotein in isolated rat brain capillaries and human and rat brain microvessel endothelial cells (Q36512766) (← links)
- Use of in vitro transporter assays to understand hepatic and renal disposition of new drug candidates (Q36544962) (← links)
- Active transport across the human placenta: impact on drug efficacy and toxicity (Q36545029) (← links)
- Recent progress toward nonpeptide ligands for the melanocortin-4 receptor (Q36729120) (← links)
- Epigenetic Modulation of Mood Disorders (Q36737217) (← links)
- Safety and efficacy of paliperidone extended-release in acute and maintenance treatment of schizophrenia (Q36873906) (← links)
- Genetic mouse models to study blood-brain barrier development and function (Q36909576) (← links)
- Coexistence of passive and proton antiporter-mediated processes in nicotine transport at the mouse blood-brain barrier. (Q36910582) (← links)
- Prediction of human pharmacokinetics--evaluation of methods for prediction of volume of distribution (Q36947315) (← links)
- ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice (Q36954728) (← links)
- The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia (Q36984231) (← links)
- The emerging importance of transporter proteins in the psychopharmacological treatment of the pregnant patient. (Q37024001) (← links)
- Mitochondrial Dysfunction in Gliomas: Pharmacotherapeutic Potential of Natural Compounds (Q37168749) (← links)
- Drug interactions at the blood-brain barrier: fact or fantasy? (Q37362486) (← links)
- Drug transporters: gatekeepers controlling access of xenobiotics to the cellular interior (Q37514340) (← links)
- Pharmacogenetics of membrane transporters: an update on current approaches (Q37641869) (← links)
- Cell-based in vitro blood-brain barrier model can rapidly evaluate nanoparticles' brain permeability in association with particle size and surface modification (Q37645105) (← links)
- Assessing brain free fraction in early drug discovery (Q37681555) (← links)